Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions

4 new insight briefs featuring Bioanalytical and ADME innovations

Learn ways to propel your drug development programs with proven bioanalytical strategies and techniques in our four new insight briefs:

Using 2 Advanced Techniques for Protein BioanalysisUsing Advanced Techniques for Protein bioanalysis insight brief

How are High Resolution Mass Spectrometry (HRMS) and Hybrid Immunoaffinity Liquid Chromatography-Mass Spectrometry (IA-LC-MS) driving unprecedented levels of precision and accuracy for protein bioanalysis? Hear from our LCMS Biologics and Biomarkers expert to learn more about how Q2 Solutions incorporates these technologies in our methodologies to drive solutions for customers’ drug development challenges. 


Immunogenicity Testing in Biologics R&D: What’s Your Strategy?

Immunogenicity testing can be a crucial component of your product’s development and success. Hear from our bioanalytical and ADME immunoassay services director to learn about the importance of immunogenicity assays in biologics R&D, as well as a key step in interpreting a therapy’s efficacy and safety. 


ADME Screening Services: Key Factors to ConsiderThinking of offshoring your ADME screening services insight brief

Selecting the right partner for ADME services is a key component of an effective drug discovery partnership. Having delivered more than 76,000 in vitro screening assays in the last year, learn 7 key advantages of partnering with Q2 Solutions as your ADME screening service in our new insight brief.


Bioanalysis: How to Adapt in an Evolving MarketAdapting and evolving in an Era of biologic growth insight brief

Hear from our senior scientific director to discover how we employ a diverse set of capabilities, including ADME investigations of new small molecule drugs, biomarker analysis and immunogenicity risk assessments to challenge historical approaches and further bioanalysis for new drug therapies.


Having a partner that is staffed by scientists with extensive experience in advanced bioanalysis techniques and strategies, as well as thorough knowledge of regulatory guidelines and best practices, is a necessity in the rapidly growing healthcare landscape. 

Contact us to learn more about how we employ a diverse set of capabilities, including ADME investigations of new small molecule drugs, biomarker analysis and immunogenicity risk assessments to remain an industry leader and further bioanalysis for new drug therapies.
Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Best Practices for Integrating Biomarkers across the Drug Development Continuum

A roadmap for a successful biomarker strategy

In Vitro ADME & Metabolite Identification Services List

Services to support your ADME development needs

Fit for Purpose Development and Validation of a Urea Biomarker Assay to Support Pre-Clinical Studies

Finding a suitable assay for measuring urea levels during human clinical trials

Read More